Welcome to our dedicated page for Rapport Therapeutics SEC filings (Ticker: RAPP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Rapport Therapeutics, Inc. (Nasdaq: RAPP) provides access to the company’s official regulatory disclosures as a clinical-stage biotechnology issuer. Rapport’s common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on The Nasdaq Global Market under the symbol RAPP, so its filings offer detailed information on its precision neuroscience business and capital markets activity.
Through this page, readers can review Form 10-K and Form 10-Q reports (when filed) for discussions of Rapport’s RAP technology platform, the development of RAP-219 for drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain, and additional programs in chronic pain, migraine, and hearing or vestibular disorders. These periodic reports also describe risk factors, research and development expenses, and other elements of the company’s operating profile.
Frequent Form 8-K filings from RAPP document material events such as positive Phase 2a trial results for RAP-219 in focal onset seizures, new data analyses presented at scientific meetings, public offerings of common stock under an effective shelf registration statement on Form S-3, and quarterly financial results and business updates. Some 8-Ks also summarize regulatory developments, including clinical holds, end-of-Phase 2 planning, and changes to at-the-market sales arrangements.
Investors can also use this page to locate information related to shareholder meetings and voting outcomes, as disclosed in 8-K items covering submissions of matters to a vote of security holders. Insider transaction reports on Form 4, when available, complement these filings by showing equity activity by directors and officers.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings, highlight clinical and financial milestones, and make it easier to understand how new disclosures may relate to Rapport’s RAP-219 program and broader precision neuroscience pipeline. Real-time updates from EDGAR help ensure that new RAPP filings, including 10-K, 10-Q, 8-K, and Form 4 submissions, are quickly accessible in one place.
Director Paul Steven M reported purchases of Rapport Therapeutics, Inc. (RAPP) common stock on 09/12/2025. Two purchase entries show 28,284 shares at a weighted average price of $24.4996 and 13,382 shares at a weighted average price of $24.9712, for a combined 41,666 shares. Both holdings are reported as indirect ownership through Paul Capital Strategy III Fund LLC, with the reporting person disclaiming beneficial ownership except to the extent of any pecuniary interest. The filing discloses the price ranges for the multiple trades that produced the weighted averages and is signed by an attorney-in-fact on behalf of the reporting person.
Wendy B. Young, a director of Rapport Therapeutics, Inc. (RAPP), reported a purchase of 3,500 shares of the company's common stock on 09/11/2025 at a reported price of $22.60 per share. After this transaction she beneficially owns 9,500 shares. The Form 4 filing was signed by an attorney-in-fact on 09/11/2025.
Rapport Therapeutics, Inc. (RAPP) disclosed a marketed offering of common stock to be sold by the company, with all shares in the offering sold by Rapport. The company states the offering is expected to close on or about September 11, 2025, subject to customary closing conditions.
The filing references a previously filed S-3 (file no. 333-288444) declared effective on July 9, 2025, and a final prospectus supplement dated September 9, 2025 filed on September 10, 2025. An underwriting agreement dated September 9, 2025 names Goldman Sachs, Jefferies, TD Securities (USA) and Stifel as bookrunners. The filing also notes legal opinion and consent from Goodwin Procter LLP and includes Inline XBRL cover page data.
Rapport Therapeutics (RAPP) is offering common stock at $26.00 per share, with aggregate dollar figures shown of $250,000,010.00 and related underwriting allocations. The prospectus describes RAP-219, an AMPAR negative allosteric modulator targeting TARPγ8 for focal epilepsy, bipolar disorder and peripheral neuropathic pain. In an 8-week Phase 2a cohort of 30 patients, RAP-219 showed topline efficacy: 85.2% of patients achieved ≥30% reduction in LEs (p<0.0001), 72.0% achieved ≥50% reduction in clinical seizures (p<0.0001), and a reported 24% figure for seizure outcome in the 8-week period (p<0.0001). Safety: four discontinuations during treatment, three due to TEAEs; safety population = 30. A PET trial and MAD-2 supported target receptor occupancy and neuroanatomical specificity. The FDA placed the IND for a DPNP proof-of-concept trial on clinical hold in Q4 2024; this hold is LIMITED to DPNP and has not affected the focal epilepsy Phase 2a or planned bipolar trial. Company timelines: initiate open-label long-term safety trial by end of 2025 (prelim results H2 2026), advance two Phase 3 pivotal trials in Q3 2026, and report PK results in 2027. The prospectus notes broad management discretion over net proceeds and typical lock-up and transfer restrictions for insiders.
Rapport Therapeutics insider Cheryl Gault, the company's Chief Operating Officer, reported transactions on 09/08/2025 under a Rule 10b5-1 trading plan adopted December 11, 2024. The Form 4 shows a simultaneous option exercise and sale: 5,000 shares were acquired by exercise of stock options at an exercise price of $1.80 per share and 5,000 shares were sold the same day at $38.33 per share.
After these transactions Ms. Gault directly beneficially owns 171,928 shares of common stock and holds 110,407 shares underlying outstanding options. The option grant vests 25% on August 7, 2024, with the remainder vesting monthly over 36 months, and the exercised options expire December 5, 2033.
Rapport Therapeutics describes RAP-219, an AMPAR negative allosteric modulator designed to target TARPγ8 to achieve neuroanatomical specificity for focal epilepsy and other CNS indications. In a Phase 2a safety population of 30 patients, the company reports topline efficacy in refractory focal-onset seizures: 85.2% of patients achieved ≥30% reduction in LEs and 72.0% achieved ≥50% reduction (both p<0.0001); median and higher-responder results were reported and detailed follow-up analyses are ongoing. The company states RAP-219 was generally well tolerated with four discontinuations during treatment, three attributed to TEAEs.
The filing also discloses an FDA clinical hold specific to the IND for diabetic peripheral neuropathic pain that requested protocol amendments; this hold has not affected the ongoing focal epilepsy trial. The company outlines development plans including additional follow-up results, a long-term safety trial, planned Phase 3 initiation, and further PK and PET data releases as part of its clinical pathway. The prospectus supplement stresses risks, forward-looking uncertainties, and references incorporated SEC filings for more detail.
Rapport Therapeutics (RAPP) Form 144 notice reports a proposed sale of common stock. The filer intends to sell 10,000 shares through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $143,600. The shares represent a portion of 36,497,920 shares outstanding. The securities were acquired and are to be sold on 09/08/2025 following an exercise of stock options, with cash payment recorded. The filer certifies no undisclosed material adverse information and provides the required Rule 144 representations.
Rapport Therapeutics, Inc. filed an 8-K stating that, effective September 8, 2025, it terminated the sales agreement prospectus tied to its Form S-3 registration statement (File No. 333-288444) for common stock sales through Leerink Partners LLC and Cantor Fitzgerald & Co.
The underlying Sales Agreement dated July 1, 2025 remains in full force and effect, but the company cannot sell common stock under it unless a new prospectus, prospectus supplement or new registration statement is filed. As of September 8, 2025, the company had not issued or sold any shares under this Sales Agreement.
Rapport Therapeutics reported topline Phase 2a efficacy for RAP-219 in drug-resistant focal onset seizures showing strong short-term clinical responses. In the 8-week treatment period, 85.2% of patients achieved a ≥30% reduction in lifetime events (LEs) from baseline, 72.0% achieved a ≥50% reduction in clinical seizures, and 24% achieved seizure freedom; all responder endpoints reported p<0.0001. Median reductions were assessed versus appropriate null hypotheses using Wilcoxon signed rank tests and exact binomial tests for responder rates.
The company said RAP-219 was generally well-tolerated with mostly mild treatment-emergent adverse events and a low discontinuation rate. Rapport noted ongoing 8-week follow-up, plans for Phase 3 trials in focal onset seizures, a Phase 2 bipolar mania study, exploration of a long-acting injectable formulation, and expects initial pharmacokinetic results in 2027. A press release and corporate presentation were furnished and a webcast presentation will be posted on the company website.
Rapport Therapeutics Chief Scientific Officer David Bredt reported sales of common stock under a Rule 10b5-1 plan adopted December 12, 2024. On 08/15/2025 he sold 8,300 shares at a weighted-average price of $14.9769 (trade prices ranged $14.65–$15.50) and sold 200 shares at a weighted-average price of $15.79 (trade prices ranged $15.74–$15.84). The filings show beneficial ownership following those transactions of 426,842 and 426,642 shares, respectively. The Form 4 was signed by attorney-in-fact Troy Ignelzi on 08/18/2025.